By Alan Hamilton Labour Staff, By George Clark Political Correspondent, By Edward Townsend Business News Staff, From Eric Marsden, By A. M. Rendel Diplomatic Correspondent, By Our Business News Staff, From Robert Fisk, By Our Political Staff, By Our Legal Correspondent, By Tim Devlin Education Correspondent, From Martin Huckerby, By Pat Healy Social Services Correspondent, By Marcel Berlins Legal Correspondent, By Michael Baily Transport Correspondent, From David Cross, From Alan McGregor, From Our Own Correspondent, From Gretel Spitzer, From Our Correspondent, From Fred Emery, From Edmund Stevens, Frem Our Correspondent, From Victoria Brittain, From David Bonavia, From Michael Hornsby, From Norman Fox, From Neil Allen, From a Special Correspondent, From Rex Bellamy Tennis Correspondent, By Sydney Friskin, From John Woodcock Cricket Correspondent, By Jim Railton, By Dennis Bird, By Michael Phillips Racing Correspondent, By Jim Snow Northern Racing Correspondent, by Prudence Glynn, Paul Overy, Irving Wardle, Richard Maylan, Leonard Buckley, Alan Blyth, Philip Howard, Bernard Levin, Edward Mortimer, PHS, Mario Modiano, R. K. M. KENNEDY, , HUGH DYKES., R. E. RUSHEN., STONEHAVEN, , DAVID GOODENDAY., D. LAWSON HILL, Managing Director, Watercraft-Viking Limited., A. COOPER., Your obedient servant, , MARTYN DYER., MARK BALDWIN., E. MACK, , TONY FIRTH, GAY FIRTH., ANTHONY SARGENT., LAURENCE KITCHIN, Professor of Liberal Arts., JOHN JOLLIFFE, , RALPH TURVEY, , P. N. GERRARD, , JOHN KENNETH GALBRAITH, , W. G. HAYTER, , NICHOLAS HINDE, , By Geraldine Norman Sale Room Correspondent, By Our Medical Correspondent., By Christopher Warman Local Government Correspondent, By Tim Congdon, By Our Financial Staff, By Peter Hill, By Maurice Corina Industrial Editor, By Business News Staff, By Maurice Barnfather, By Our Industrial Editor., By Roger Vielvoye, By Margaret Drummond, From Anthony Thomas., By Christopher Wilkins, By John Groser, Kenneth Owen, From Anthony Thomas, GORDON WARD., JAMES T. ANDERSON., From Frank Vogl, K. H. N. BULMER., ALAN J. COCKERILL, , ROBERT ZAGER., G. STONE, , BY THE FINANCIAL EDITOR, Shona Crawford-Poole, Oliver Stanley, Christopher Wilkins,
... family' sold for £7,500, Soviet test of MIRV missile over Pacific, Community tax on French farm ...
1974 - Gale Group | TDA
Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Susana Banerjee, Sandro Pignata, Nicoletta Colombo, John W. Moroney, Casey Cosgrove, Jung‐Yun Lee, A. Roszak, Shani Breuer, Jacqueline M. Tromp, Diana Bello-Roufai, Lucy Gilbert, Rowan Miller, Tashanna Myers, Yuemei Wang, Anna Berkenblit, Domenica Lorusso, Toon Van Gorp,
LBA5507 Background: Mirvetuximab soravtansine (MIRV), an antibody drug conjugate targeting FRα, demonstrated clinically meaningful antitumor activity in a single arm trial reported previously (Matulonis, JCO ... phase 3 trial to confirm the efficacy of MIRV vs standard-of-care chemotherapy in patients (pts) ... 1-3 priors were randomized 1:1 to MIRV 6 mg/kg, adjusted ideal body weight, Day ... 6, 2023, 227 pts were randomized to the MIRV arm; 226 to the IC arm. Median follow- ... 0.860). The adverse event (AE) profile of MIRV was consistent with prior reports: predominantly low-grade ...
Tópico(s): Cancer Genomics and Diagnostics
2023 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Marie M. Proebster, B.T. Cockayne, H.J. Macmoolson, George B. Sloan, R.G. King, David Morse, R.M. Bale, Stephen E. South,
... sets off a lot of worries Up Goes Mirv A man for most Democrats Election '68 No ...
1968 - Gale Group | The Economist
Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Giovanni Scambia, Domenica Lorusso, Robin Farias‐Eisner, Susana Banerjee, Conleth G. Murphy, János L. Tanyi, Hal W. Hirte, Jason Konner, Peter Lim, Monica Prasad Hayes, Bradley J. Monk, S. Kim, Jiao Wang, Patricia Pautier, I. Vergote, Michael J. Birrer,
Abstract Background Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. FORWARD ... III study, evaluated the safety and efficacy of MIRV compared to chemotherapy in pts with PROC. Methods ... were enrolled. Pts were randomized 2:1 to MIRV (6 mg/kg, adjusted ideal body weight) once ... months. Results Of 366 pts randomized, 248 received MIRV and 118 chemotherapy. Baseline characteristics were well balanced ... of 4.1 vs 4.4 months for MIRV and chemotherapy, respectively). For the high FRα pt ...
Tópico(s): Peptidase Inhibition and Analysis
2019 - Elsevier BV | Annals of Oncology
B.A. Lewis, T.E. Foulkes, C. Schalburg, Charles Janson, J.K. Quill, Geoffrey Picot, J.L. Kateka, Richard J. Calhoun, Abdul Qayyum, P. Mcwilliams,
... Appointments International Appointments Property Dodwell It's a Mirv world A push in the Balkans Now that ...
1974 - Gale Group | The Economist
Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Yolanda García García, Susana Banerjee, Domenica Lorusso, Jung‐Yun Lee, John W. Moroney, Nicoletta Colombo, A. Roszak, Jacqueline M. Tromp, Tashanna Myers, Jeong‐Won Lee, Mario Beiner, Casey Cosgrove, David Cibula, Lainie P. Martin, Renaud Sabatier, Joseph Buscema, Purificación Estévez-García, Lan Coffman, Shibani Nicum, Linda Duska, Sandro Pignata, Fernando Gálvez, Yuemei Wang, Michael Method, Anna Berkenblit, Diana Bello Roufai, Toon Van Gorp,
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum- ... trial to compare the efficacy and safety of MIRV with the investigator's choice of chemotherapy in ... assigned in a 1:1 ratio to receive MIRV (6 mg per kilogram of adjusted ideal body ... participants underwent randomization; 227 were assigned to the MIRV group and 226 to the chemotherapy group. The ... interval [CI], 4.34 to 5.95) with MIRV and 3.98 months (95% CI, 2.86 ...
Tópico(s): Lymphoma Diagnosis and Treatment
2023 - Massachusetts Medical Society | New England Journal of Medicine
Giorgio Bogani, Robert L. Coleman, Ignace Vergote, Toon Van Gorp, Isabelle Ray‐Coquard, Ana Oaknin, Ursula A. Matulonis, David M. O’Malley, Francesco Raspagliesi, Giovanni Scambia, Bradley J. Monk,
Mirvetuximab soravtansine-gynx (MIRV) is a conjugate of a folate receptor alpha (FRα)-directed antibody and the maytansinoid microtubule inhibitor, DM4. Accumulating pre- ... supported the safety and anti-tumor activity of MIRV in tumors expressing FRα. In 2017, a phase I expansion study reported the first experience of MIRV in FRα-positive platinum-resistant ovarian cancer with ... study failed to demonstrate a significant benefit of MIRV in FRα-positive tumors. On the basis of the data reported from this latter study, MIRV was then explored in the FRα-high population ...
Tópico(s): Toxin Mechanisms and Immunotoxins
2023 - BMJ | International Journal of Gynecological Cancer
Ursula A. Matulonis, Ana Oaknin, Sandro Pignata, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, Michael Method, Brooke Esteves, Robert L. Coleman, Domenica Lorusso,
... a global single arm phase 3 study evaluating MIRV in patients (pts) with FRα high platinum-resistant ovarian cancer (PROC). MIRV is an antibody drug conjugate comprising a FRα- ... a potent tubulin-targeting agent. In this study, MIRV demonstrated activity in a broad population of PROC, ... therapies, including required prior bevacizumab. Pts received intravenous MIRV at 6 mg/kg, adjusted ideal body weight, ... 6, 7.7). With 15 responders remaining on MIRV, the DOR continues to evolve. In the 86 ... to an ocular event. The tolerability profile of MIRV consists of low-grade, reversible ocular and GI ...
Tópico(s): HER2/EGFR in Cancer Research
2022 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Giovanni Scambia, Domenica Lorusso, Gottfried E. Konecny, Susana Banerjee, Conleth G. Murphy, János L. Tanyi, Hal W. Hirte, Jason Konner, Peter Lim, Monica Prasad-Hayes, Bradley J. Monk, Patricia Pautier, Jiao Wang, Anna Berkenblit, Ignace Vergote, Michael J. Birrer,
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid ... open-label, phase III study FORWARD I compared MIRV and investigator's choice chemotherapy in patients with ... assigned, in a 2 : 1 ratio, to receive MIRV (6 mg/kg, adjusted ideal body weight) or ... total of 366 patients were randomized; 243 received MIRV and 109 received chemotherapy. The primary endpoint, PFS, ... 0.69, P = 0.049). Superior outcomes for MIRV over chemotherapy were observed in all secondary endpoints ...
Tópico(s): HER2/EGFR in Cancer Research
2021 - Elsevier BV | Annals of Oncology
Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert E. Coleman,
... limited clinical activity and considerable toxicity. Mirvetuximab soravtansine (MIRV) is an antibody drug conjugate (ADC) comprising a ... a global single arm phase 3 study evaluating MIRV in adult patients (pts) with FRα high platinum- ... therapies, including required prior bevacizumab. Pts received intravenous MIRV at 6 mg/kg, adjusted ideal body weight, ... 6, 7.7). With 15 responders remaining on MIRV at the time of the data cutoff, the ... limited clinical activity and considerable toxicity. Mirvetuximab soravtansine (MIRV) is an antibody drug conjugate (ADC) comprising a ...
Tópico(s): Renal cell carcinoma treatment
2022 - Elsevier BV | Gynecologic Oncology
David M. O’Malley, Debra L. Richardson, I. Vergote, Lucy Gilbert, Cesar M. Castro, Diane Provencher, Ursula A. Matulonis, Gina Mantia-Smaldone, Lainie P. Martin, Patrick A. Zweidler‐McKay, Kathleen N. Moore,
MIRV is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. MIRV is being evaluated with carboplatin and BEV in ... 50%/ ≥75% of cells with PS2+ staining intensity). MIRV was given at 6 mg/kg (adjusted ideal ... on Day 1 of a 21-day cycle. MIRV and BEV were continued as maintenance after completing ... AEs were consistent with the safety profile of MIRV, albeit more frequent: diarrhea (all grades, 83%; [gr ... of 11.9 mos (95% CI 9, 15). MIRV was readily combined with standard dosing of BEV ...
Tópico(s): Advanced Breast Cancer Therapies
2020 - Elsevier BV | Annals of Oncology
Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O’Malley, Ursula A. Matulonis, Gottfried E. Konecny,
Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and is indicated for ... received 1 to 3 prior systemic treatment regimens. MIRV has demonstrated single-agent anticancer activity in clinical ... adverse events (AEs). Pooled safety analysis of 464 MIRV-treated patients across 3 trials, including the phase ... 0 in patients with complete follow-up data. MIRV-associated ocular AEs were primarily characterized by resolvable ... reflects the distinctive, milder ocular safety profile for MIRV compared with that of other ADCs with ocular ...
Tópico(s): Ovarian cancer diagnosis and treatment
2023 - Elsevier BV | Gynecologic Oncology Reports
David M. O’Malley, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Patrick A. Zweidler‐McKay, Jiuzhou Wang, Brooke Esteves, Kathleen N. Moore, Lucy Gilbert,
5504 Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. As ... 1b FORWARD II trial (NCT02606305), the combination of MIRV with bevacizumab (BEV) was evaluated in pts with ... based doublet would be appropriate. Methods: Pts received MIRV (6 mg/kg; adjusted ideal body weight) and ... in ≤ 10% of pts. Conclusions: The combination of MIRV with BEV demonstrates impressive anti-tumor activity with ... These results build on data previously reported for MIRV/BEV in PROC patients ( Gyn Oncology O’Malley, ...
Tópico(s): Angiogenesis and VEGF in Cancer
2021 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Thuy Nguyen, Djeneba Fofana, Minh Patrick Lê, Charlotte Charpentier, Gilles Peytavin, Marc Wirden, Sidonie Lambert-Niclot, Nathalie Désiré, Maxime Grudé, Laurence Morand‐Joubert, Philippe Flandre, Christine Katlama, Diane Descamps, Vincent Cálvez, Ève Todesco, Anne‐Geneviève Marcelin,
... and the impact of baseline minority resistant variants (MiRVs) on the virological response to an INSTI-based ... There was no difference in prevalence of baseline MiRVs between patients with VF and those with VS. MiRVs found at baseline in patients with VF were ... more sensitive than Sanger sequencing at detecting INSTI MiRVs at treatment failure. The presence of MiRVs at failure could be important to the decision ... was no association between the presence of baseline MiRVs and the response to INSTI-based therapies in ...
Tópico(s): HIV/AIDS Research and Interventions
2018 - Oxford University Press | Journal of Antimicrobial Chemotherapy
Debra L. Richardson, Kathleen N. Moore, Ignace Vergote, Lucy Gilbert, Lainie P. Martin, Gina Mantia-Smaldone, Cesar M. Castro, Diane Provencher, Ursula A. Matulonis, James Stec, Yuemei Wang, Michael Method, David M. O’Malley,
... profile of the triplet combination of mirvetuximab soravtansine (MIRV), carboplatin, and bevacizumab in recurrent, platinum-sensitive ovarian ... cancer (1–2 prior lines of therapy) received MIRV (6 mg/kg adjusted ideal body weight), carboplatin ( ... after 6 cycles per investigator discretion; continuation of MIRV+bevacizumab as maintenance therapy was permitted. Eligibility included ... of 6, 12, and 13 cycles of carboplatin, MIRV, and bevacizumab, respectively. The confirmed objective response rate ... discontinuations occurred, and neutropenia. Conclusions This triplet regimen (MIRV+carboplatin+bevacizumab) was highly active, with a tolerable ...
Tópico(s): Endometrial and Cervical Cancer Treatments
2024 - Elsevier BV | Gynecologic Oncology
Jim Douglas Darke, Eshan M. Dandekar, Arnel Aguinaldo, Scott J. Hazelwood, Stephen M. Klisch,
... maximum external rotation, and maximum internal rotation velocity (MIRV), as well as maximum shoulder and elbow kinetics between foot contact and MIRV were compared at pitches 1-5, 34-38, ... were used to test the second hypothesis. Results: MIRV increased from pitches 1-5 to 71-75 ( P = .007), and head flexion at MIRV decreased from pitches 1-5 to 34-38 ( ... pitchers: (1) pitch speed remained steady, (2) shoulder MIRV increased, and (3) shoulder kinetics increased during a ...
Tópico(s): Elbow and Forearm Trauma Treatment
2018 - SAGE Publishing | Orthopaedic Journal of Sports Medicine
Mysore Kalappa Sudarshan, Subodh Bhardwaj, B J Mahendra, Hitt Sharma, ThittamaranahalliVaradappa Sanjay, Doddabele Hanumanthaiah Ashwathnarayana, Gangaboraiah Bilagumba,
... comparable with that of Merieux inactivated rabies vaccine (MIRV, lyophilized) which was used as a control. Subsequently, ... forty-five suspect rabid dog bite cases with MIRV as control. The vaccine was found to be equally safe and immunogenic as MIRV and showed better rabies virus neutralizing antibody (RVNA) response on day 90 than MIRV. A post-licensing study conducted on 150 cases ...
Tópico(s): Virology and Viral Diseases
2008 - Landes Bioscience | Human Vaccines
Floor Backes, Lai Wei, Larry J. Copeland, David E. Cohn, Jeffrey M. Fowler, Kristin Bixel, Casey Cosgrove, John L. Hays, Molly Myers, Kelly Dodd, David M. O’Malley,
... dose (MTD) and to describe toxicities associated with MIRV and rucaparib in patients with recurrent endometrial and ... Using a 3+3 design patients were given MIRV (4, 5, or 6 mg/kg IV every ... to establish the phase 2 dose at DL1 (MIRV 5 mg/kg IV every 3 weeks and ... response is not reached. Conclusions: Combination rucaparib and MIRV was tolerable with mostly manageable side effects. Encouraging ... dose (MTD) and to describe toxicities associated with MIRV and rucaparib in patients with recurrent endometrial and ...
Tópico(s): BRCA gene mutations in cancer
2021 - Elsevier BV | Gynecologic Oncology
Mihaela Cristea, Daphne Stewart, Timothy W. Synold, Nora Ruel, Joanne Mortimer, Wenge Wang, Alexander Jung, Sharon P. Wilczynski, Gottfried E. Konecny, Melissa Eng, Lindsay Kilpatrick, Ernest Han, Thanh H. Dellinger, Amy Hakim, Stephen Lee, Robert J. Morgan, Mark T. Wakabayashi, Paul Frankel,
... therapies. This phase I study evaluated mirvetuximab soravtansine (MIRV) and gemcitabine in patients with recurrent FRα-positive ... 25–49%) FRα expressors. The MTD/RP2D was MIRV 6 mg/kg AIBW D1 and gemcitabine 800 ... 95%CI, 0–32.1%) confirmed PR. Conclusion MIRV and gemcitabine demonstrate promising activity in platinum resistant ...
Tópico(s): Endometrial and Cervical Cancer Treatments
2024 - Elsevier BV | Gynecologic Oncology
Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, Philipp Harter, Conleth G. Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert L. Coleman,
... platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor ... phase II study evaluating efficacy and safety of MIRV in patients with PROC. METHODS SORAYA enrolled FRα- ... 33%, 20%, and 9% of patients, respectively. CONCLUSION MIRV demonstrated consistent clinically meaningful antitumor activity and favorable ...
Tópico(s): Lymphoma Diagnosis and Treatment
2023 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
David M. O’Malley, Tashanna Myers, Claudio Zamagni, Elisabeth Diver, Domenica Lorusso,
... conjugate (ADC) development in ovarian cancer. Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, ... patients with FRα positive platinum resistant ovarian cancer. MIRV in combination with BEV has demonstrated clinically meaningful ... to randomize 418 patients, 1:1 receiving intravenous MIRV at a dose of 6 mg/kg adjusted ...
Tópico(s): Advanced Breast Cancer Therapies
2023 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
... explained? Why, for example, does United States buy MIRV, despite expert testimony about grave dangers that it ... warheads, and its high immunity to aerial surveillance, MIRV can provoke a Soviet fear of an American ... and can provoke Soviets into acquiring their own MIRVs, perhaps leading again to the reciprocal fear of ...
Tópico(s): Defense, Military, and Policy Studies
2016 - American Economic Association | American Economic Review
Kozo Naito, Hiroyasu Takagi, Norimasa Yamada, Shinichi Hashimoto, Takeo Maruyama,
... forces (CEN) to maximum angular velocities of IR (MIRV) and PR (MPRV). The results showed that the contribution of MUS account for 98.0% of MIRV, while that contribution to MPRV was indicated as ... the effects of GYR, COR and CEN on MIRV are negligible. In conclusion, rapid PR motion during ...
Tópico(s): Sports Performance and Training
2014 - Elsevier BV | Human Movement Science
... idsa.in/idsacomments/IndianNuclearPostureConfusingSignalsfromDRDO_vnarang_260911; Daniel Buchonnet, “MIRV: A Brief History of Minuteman and Multiple Reentry ... 12, http://www.gwu.edu/~nsarchiv/nsa/NC/mirv/mirv.html; Rajesh Basrur, “Nuclear Weapons and India's ...
Tópico(s): Global Peace and Security Dynamics
2013 - Taylor & Francis | The Washington Quarterly
Lynn E. Davis, Warner R. Schilling,
... the variables and methods used to calculate the MIRV threat to the fixed-site land-based ICBM ... fixed-site ICBM force posed by the American MIRV program.
Tópico(s): Intelligence, Security, War Strategy
1973 - SAGE Publishing | Journal of Conflict Resolution
Since 1965 when the problem of verifying a MIRV ban was added to the charge that MIRV was a threat to deterrence stability, the case against MIRV has remained essentially unchanged. Although MIRV was defended alternatively as a cost-effective means ... chip in international negotiations, the principal charge against MIRV (counterforce threat) was never seriously disputed. Nevertheless, because ... tended to agree that prospects for a future MIRV ban are not promising. A case is made ... a ban on the most destabilizing variety of MIRVs—those on land-based ICBMs. This approach, a ...
Tópico(s): Military History and Strategy
1978 - SAGE Publishing | Journal of Conflict Resolution
K.N. Moore, D. Lorusso, Ana Oaknin, Sandro Pignata, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo, P Harter, Colin G. Murphy, Y. Tu, Fengya Zhu, B. Esteves, Michael Method, Michael J. Birrer, Robert L. Coleman, U. Matulonis, David M. O’Malley,
MIRV is a first-in-class antibody-drug conjugate comprising an FRα-binding antibody, cleavable linker, and ... of pt characteristics on the PK parameters of MIRV, DM4, and S-methyl-DM4 (SmDM4) metabolite in ... positive tumors. A base model was developed for MIRV followed by a stepwise covariate search. Structural components ... for DM4 and SmDM4 concentration data while fixing MIRV PK parameters. The final semi-mechanistic model accommodated saturable elimination of MIRV and the payload metabolite. Model construction was based ...
Tópico(s): Estrogen and related hormone effects
2022 - Elsevier BV | Annals of Oncology
K.N. Moore, A.M. Oza, N. Colombo, A. Oaknin, Giovanni Scambia, D. Lorusso, Susana Banerjee, C. Murphy, J. Konner, P. Lim, M. Prasad-Hayes, B.J. Monk, J. Wang, M.J. Birrer, I.B. Vergote,
MIRV, a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is currently under investigation ... at week 8/9 in pts treated with MIRV vs chemotherapy (CTX) (31.7% vs 14.0%; ... of GI symptom deterioration was 70% lower with MIRV compared with CTX (P = 0.0007). Analyses of ... a statistically significant benefit in physical functioning for MIRV over CTX (P= 0.0369). There were improvements ... ovarian cancer-specific symptoms on the FOSI, for MIRV vs CTX. In the FRα-high population, analysis ... OV28 also demonstrated improvement in GI symptoms for MIRV vs CTX, although this did not achieve statistical ...
Tópico(s): Ovarian cancer diagnosis and treatment
2022 - Elsevier BV | Annals of Oncology
Jia Mai, Limei Wu, Ling Yang, Ting Sun, Xiaojuan Liu, Rutie Yin, Yongmei Jiang, Jinke Li, Qintong Li,
... various FRα-based therapeutics. We highlight mirvetuximab soravtansine (MIRV), or Elahere (ImmunoGen), the first FRα-targeting ADC ... and management of ocular adverse events associated with MIRV administration.
Tópico(s): Cancer-related Molecular Pathways
2023 - Frontiers Media | Frontiers in Immunology
Anca Chelariu-Raicu, Sven� Mahner, Kathleen N. Moore, Domenica Lorusso, Robert L. Coleman,
... November 2022, by the approval of mirvetuximab soravtansine (MIRV) for adult patients with folate receptor alpha (FRα) ... including results from late-stage development trials investigating MIRV in ovarian cancer and TV in cervical cancer. ...
Tópico(s): Lymphoma Diagnosis and Treatment
2023 - BMJ | International Journal of Gynecological Cancer